Aegerion price target raised to $69 from $48 at JPMorgan

theflyonthewall.com

JPMorgan raised its price target for Aegerion citing the recent Juxtapid price increase and encouraging physician feedback. The firm keeps an Overweight rating on the stock.

View Comments (0)